Tower Research Capital (TRC)’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-16,363
| Closed | -$3.6K | – | 6480 |
|
|
2023
Q2 | $3.6K | Buy |
16,363
+14,779
| +933% | +$3.4K | ﹤0.01% | 5044 |
|
|
2023
Q1 | $0 | Sell |
1,584
-8,046
| -84% | -$5.84K | ﹤0.01% | 6580 |
|
|
2022
Q4 | $11K | Sell |
9,630
-1,039
| -10% | -$1K | ﹤0.01% | 3925 |
|
|
2022
Q3 | $10K | Buy |
10,669
+2,592
| +32% | +$4.03K | ﹤0.01% | 4612 |
|
|
2022
Q2 | $9K | Buy |
8,077
+4,820
| +148% | +$5.99K | ﹤0.01% | 4623 |
|
|
2022
Q1 | $6K | Buy |
3,257
+3,044
| +1,429% | +$5.76K | ﹤0.01% | 4976 |
|
|
2021
Q4 | $0 | Sell |
213
-1,486
| -87% | -$4.23K | ﹤0.01% | 6787 |
|
|
2021
Q3 | $6K | Buy |
1,699
+647
| +62% | +$2.99K | ﹤0.01% | 4796 |
|
|
2021
Q2 | $8K | Buy |
+1,052
| New | +$6.57K | ﹤0.01% | 4526 |
|
|
2021
Q1 | – | Sell |
-653
| Closed | -$4K | – | 5857 |
|
|
2020
Q4 | $4K | Buy |
+653
| New | +$4.56K | ﹤0.01% | 4746 |
|
|
2019
Q3 | – | Sell |
-38
| Closed | – | – | 4654 |
|
|
2019
Q2 | $0 | Buy |
+38
| New | +$366 | ﹤0.01% | 4492 |
|
|
2019
Q1 | – | Sell |
-158
| Closed | -$2K | – | 4461 |
|
|
2018
Q4 | $2K | Sell |
158
-467
| -75% | -$5.33K | ﹤0.01% | 3471 |
|
|
2018
Q3 | $8K | Buy |
+625
| New | +$8.08K | ﹤0.01% | 2919 |
|
Other funds holding ARDS
Tower Research Capital (TRC)'s ARDS Position: Q3 2023 in Review
Tower Research Capital (TRC) sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2023, closing a stake of 16,363 shares — an estimated $3.6K sold.
Tower Research Capital (TRC) first reported a position in ARDS in Q3 2018 and held it in 13 quarters. The position peaked at $11K in Q4 2022. 1 fund tracked by Wall St. Rank holds ARDS as of Q3 2023.
- Tower Research Capital (TRC) reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Tower Research Capital (TRC) sold 16,363 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2023, an estimated $3.6K.
- Tower Research Capital (TRC) first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q3 2018 and held it in 13 quarters.
- Tower Research Capital (TRC)'s Aridis Pharmaceuticals Inc. Common Stock position peaked at $11K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2023.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2023, filed 14 Nov 2023.